HBV

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

Retrieved on: 
Wednesday, February 16, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, NASDAQ, RSV, Tissue, HCV, Medication, U.S. Securities and Exchange Commission, Vaccine, Security (finance), Glecaprevir/pibrentasvir, Safety, Risk, Degenerative disease, Institute of Liver and Biliary Sciences, MAD, AbbVie, SAD, Marketing, Human, Pharmacokinetics, Patent, Hepatitis B virus, Respiratory syncytial virus, Research, Drug discovery, Severe acute respiratory syndrome coronavirus 2, COVID-19, Epithelium, HBV, Industry, Pharmaceutical industry

SARS-CoV-2 continues to infect millions of individuals worldwide and new variants are still emerging, highlighting the limitations of current therapies and vaccines for COVID-19.

Key Points: 
  • SARS-CoV-2 continues to infect millions of individuals worldwide and new variants are still emerging, highlighting the limitations of current therapies and vaccines for COVID-19.
  • We are excited to reach this milestone and begin our EDP-235 clinical program, with the first subject being dosed in this Phase 1 study.
  • All SAD and MAD cohorts will enroll eight participants who will be randomized to receive EDP-235 or placebo in a 3:1 ratio.
  • This press release contains forward-looking statements, including statements with respect to the prospects for advancement of EDP-235 for COVID-19.

Human Immunodeficiency Virus (HIV) Epidemiology Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 15, 2022
Infectious Diseases, AIDS, Health, ART, HIV, Sex, Incidence, Prevalence, HCV, Epidemiology, Risk, Coinfection, Hepatitis B virus, Pre-exposure prophylaxis, HBV, Vaccine, Dietary supplement

The "Human Immunodeficiency Virus (HIV) - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human Immunodeficiency Virus (HIV) - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The Human Immunodeficiency Virus (HIV) Epidemiology Report provides an overview of the risk factors, comorbidities, and global trends of HIV in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • Diagnosed prevalent cases are further segmented by coinfection with hepatitis B virus (HBV), coinfection with hepatitis C virus (HCV), and cases on antiretroviral therapy (ART).
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in HIV.

Hepion Pharmaceuticals to Present at BIO CEO & Investor Conference

Retrieved on: 
Monday, February 14, 2022
NASDAQ, Metabolomics, Patient, HDV, Ill, Food, Cirrhosis, Response, Company, HEPA, HCV, New York Marriott Marquis, Precision medicine, IND, Fatty liver disease, Hepatocellular carcinoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Genomics, Proteomics, NASH, Lipidomics, Cyclophilin, HCC, Liver disease, BIO, Conference, Artificial intelligence, HBV, Fast Track, GLOBE, Pharmaceutical industry, Omics

EDISON, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (AI)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), announced today that its CEO, Dr. Robert Foster, will present a corporate overview at the BIO CEO & Investor Conference on Tuesday, Feburary 15, 2022 at 11:15 a.m. Eastern Time at the New York Marriott Marquis.

Key Points: 
  • EDISON, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (AI)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), announced today that its CEO, Dr. Robert Foster, will present a corporate overview at the BIO CEO & Investor Conference on Tuesday, Feburary 15, 2022 at 11:15 a.m. Eastern Time at the New York Marriott Marquis.
  • The Company's lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes.
  • In November 2021, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for rencofilstat for the treatment of NASH.
  • Hepion intends to use AI-POWR to help identify which NASH patients will best respond to rencofilstat, potentially shortening development timelines and increasing the delta between placebo and treatment groups.

VaxCorps to Expand Vaccine Site Network in 2022

Retrieved on: 
Monday, February 14, 2022
Manna, Benchmark, Centricity, Patient, CEO, CMV, HSV, Achievement, Escherichia coli, Smallpox, Congress, III, Goal, Safety, Globe, Clinical pharmacology, Clinical trial, Research, AVA, COVID-19, HBV, Industry, Pharmaceutical industry, Pain, Neurology, Dermatology, Psychiatry

With this expansive addition to the network, VaxCorps continues to grow its geographic access to diverse patient populations.

Key Points: 
  • With this expansive addition to the network, VaxCorps continues to grow its geographic access to diverse patient populations.
  • VaxCorps, who is a silver sponsor for this year's World Vaccine Congress, has achieved a dignified title of having the most ViE wins for a clinical research network.
  • Additionally, the VaxCorps global network was the first to have at least one company participate in over 97% of all vaccine trials during that period.
  • This is an exciting achievement to have going into World Vaccine Congress 2022 and we hope to earn your vote as Best Clinical Trial Network. "

Enanta Pharmaceuticals to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Retrieved on: 
Thursday, February 10, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, NASDAQ, HCV, Conference, Research, HBV, RSV, Human, Medication, Degenerative disease, SVB, Respiratory syncytial virus, AbbVie, Severe acute respiratory syndrome coronavirus 2, Institute of Liver and Biliary Sciences, Webcast, Glecaprevir/pibrentasvir, Hepatitis B virus, View, Drug discovery, COVID-19, Pharmaceutical industry

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 3:00 p.m.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 3:00 p.m.
  • A live webcast of the event will be accessible by visiting the Events and Presentations section on the Investors page of Enantas website at www.enanta.com .
  • A replay of the webcast will be available following the event and will be archived for at least 90 days.
  • Enantas research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.

DGAP-News: AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus

Retrieved on: 
Wednesday, February 9, 2022
MSD, ASO, Cytomegalovirus, LUMC, RNA, Department, BK, BK virus, Leiden University Medical Center, Transplant, Kidney, Drug of last resort, Nephrology, HBV, Lists of diseases, Company, Holm–Bonferroni method, HSV, Cancer, Infection, Degenerative disease, Therapy, Enzyme, BKV, Program, CMV, Risk, Patient, HCMV, Survival, Hospital, RNA transfection, Severe acute respiratory syndrome coronavirus 2, CEO, Letermovir, Kidney transplantation, Hemorrhagic cystitis, Oligonucleotide, Pritelivir, Virus, Immunodeficiency, Hepatitis B virus, Bone marrow, Pharmaceutical industry, Vaccine, Hybridisation, Bayer, EU, Antisense Oligonucleotide (ASO) technology, AiCuris Anti-infective Cures AG, Hybridize Therapeutics, ANTISENSE OLIGONUCLEOTIDE (ASO) TECHNOLOGY, AICURIS ANTI-INFECTIVE CURES AG, HYBRIDIZE THERAPEUTICS

Under the terms of the agreement, AiCuris will gain exclusive rights to develop and commercialize Hybridize's BKV program, with focus on the treatment of BK virus-mediated nephropathy in renal transplant patients.

Key Points: 
  • Under the terms of the agreement, AiCuris will gain exclusive rights to develop and commercialize Hybridize's BKV program, with focus on the treatment of BK virus-mediated nephropathy in renal transplant patients.
  • Hybridize and AiCuris will collaborate in the further development of the BKV-targeting therapy until the start of clinical studies, which is expected within two years.
  • "BK virus is difficult to treat as it is not addressable using conventional approaches such as classical enzyme inhibitors.
  • Hybridize has merged these areas in its mission, focusing on helping patients overcome untreated kidney diseases with high unmet medical needs using RNA-based therapeutics.

Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, February 9, 2022
Securities Act of 1933, GLOBE, Degenerative disease, Conference, HBV, U.S. Securities and Exchange Commission, AO, Annual report, SVB, SAN, Sumathi Best Television Current Reporting Award, Patient, Safety, Assembly, SEC, Securities Exchange Act of 1934, Therapy, Hepatitis B virus, MD, COVID-19, Pharmaceutical industry

A live webcast of the fireside chat can be accessed in the Events and Presentations section of the Companys website at www.assemblybio.com .

Key Points: 
  • A live webcast of the fireside chat can be accessed in the Events and Presentations section of the Companys website at www.assemblybio.com .
  • The archived webcast will be available for replay for at least 30 days.
  • Assembly Bio is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide.
  • Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

HOOKIPA to Present at the SVB Leerink Global Healthcare Conference

Retrieved on: 
Wednesday, February 9, 2022
NASDAQ, Private Securities Litigation Reform Act, GLOBE, Arenavirus, Forward-looking statement, KRAS, Gilead, Prostate cancer, Social media, Conference, Research, HBV, Investor, Cancer, HIV, Technology, Patient, Review, Security (finance), SEC, Immunotherapy, Lung, Therapy, Coronavirus, COVID-19, Online shopping, Pharmaceutical industry

NEW YORK and VIENNA, Austria, Feb. 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in the virtual 11th Annual SVB Leerink Global Healthcare Conference, February 14 - 18, 2022.

Key Points: 
  • NEW YORK and VIENNA, Austria, Feb. 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in the virtual 11th Annual SVB Leerink Global Healthcare Conference, February 14 - 18, 2022.
  • The webcast of the presentation will be available within the Investors & Media section of HOOKIPAs website at https://ir.hookipapharma.com/events .
  • HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies that mobilize and amplify targeted T cells to address unmet needs in cancer.
  • The company is leveraging its proprietary, versatile platform to engineer a broad pipeline of differentiated arenaviral therapeutics.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on: 
Tuesday, February 8, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, NASDAQ, Omicron, Industry, RNA, Patent, CARES Act, U.S. Securities and Exchange Commission, Income, HCV, Income tax, COPD, Research, HBV, RSV, COVID-19, Epithelium, Human, Delta, Marketing, Medication, Degenerative disease, Asthma, Upper respiratory tract infection, Respiratory syncytial virus, FDA, Patient, Tissue, Security (finance), AbbVie, Adult, Severe acute respiratory syndrome coronavirus 2, Population, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, Institute of Liver and Biliary Sciences, Calendar, Glecaprevir/pibrentasvir, Drug discovery, Food, Immunodeficiency, Hepatitis B virus, Infection, Urinary tract infection, Pharmaceutical industry, Animal, Vaccine, RSVP

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal first quarter ended December 31, 2021.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal first quarter ended December 31, 2021.
  • We believe that a potent core inhibitor such as EDP-514 will be an important component of a successful combination treatment regimen.
  • For the three months ended December 31, 2020, total royalty revenue was $31.7 million on AbbVies sales of MAVYRET/MAVIRET.
  • Research and development expenses totaled $48.5 million for the three months ended December 31, 2021, compared to $36.7 million for the three months ended December 31, 2020.

Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, February 8, 2022
Health, Communications, Infectious Diseases, General Health, Clinical Trials, Pharmaceutical, Public Relations, Investor Relations, MicroRNA, Glycogen storage disease type III, RNA, Patent, Cystic Fibrosis Foundation, OTC, III, Conference, HBV, NASH, COVID-19, Twitter, SVB, Investor relations, Cystic fibrosis, Gene editing, Liver, RNA transfection, Severe acute respiratory syndrome coronavirus 2, Wright Investors' Service Holdings, Inc., Infection, DNA, GSD, CureVac, Janssen Pharmaceuticals, Therapy, Nasdaq, Vaccine, Duke–NUS Medical School, Johnson & Johnson, LinkedIn, ARCT, Hepatitis B virus, Q&A, Messenger RNA, Fatty liver disease, Takeda Pharmaceutical Company, Arcturus

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that members of the Companys management team will be participating in the SVB Leerink 11th Annual Global Healthcare Conference 2022.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that members of the Companys management team will be participating in the SVB Leerink 11th Annual Global Healthcare Conference 2022.
  • Joseph Payne and Andrew Sassine, the chief executive and chief financial officers of Arcturus, respectively, will provide a corporate overview followed by a moderated Q&A on Friday, February 18th at 12:00 pm ET.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (with patents and patent applications issued in the U.S., Europe, Japan, China and other countries).